Home » Topics » Musculoskeletal, BioWorld Science

Musculoskeletal, BioWorld Science
RSS

Immune Response announces phase IIb trial results for RA

Dec. 23, 1998

New cell adhesion inhibitors in development at Lilly for inflammatory disorders, etc.

Dec. 22, 1998

Another group of MMP inhibitors discovered at Hoechst

Dec. 22, 1998

Compounds for inhibiting matrix metalloproteinases in development at Hoechst Marion Roussel

Dec. 21, 1998

Boehringer Ingelheim submits U.S. NDA for osteoarthritis treatment

Dec. 18, 1998

MMP inhibitors synthesized and evaluated for biological activity at Hoechst Marion Roussel

Dec. 17, 1998

PLA2 inhibitors with broad potential application as antiinflammatory agents

Dec. 16, 1998

Cytogen obtains expanded rights to samarium Sm 153 lexidronam for RA

Dec. 11, 1998

Immune Response receives broader patent protection for RA vaccine technology

Dec. 10, 1998

New approval obtained for Nycomed's Xefo

Dec. 9, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 29, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 30, 2026
Investors bet on transformative BCI tech for neuro disorders
BioWorld
An estimated $2 billion has been invested in the brain-computer interface (BCI) space in the last two years and the level of funding is expected to continue....
BIO 2026: Alternatives to funding orphan drugs
BioWorld
At the BIO International Convention, nonprofit and for-profit companies discussed ways to fund orphan drug development, especially for ultra-rare diseases where...
CINP 2026: Gut microbiota could predict antidepressant response
BioWorld
The gut microbiota may be altered in people with depression as a result of treatment. These microorganisms reorganize differently in individuals who respond to...